pharm edaily

[Shin-Min Joon, Edaily Reporter] Huons USA of Huons Group promoted the Group’s drug products and innovative new drug candidates (pipelines) at global pharmaceutical exhibition.

Huons USA participated in ‘CPHI Americas’ held in Pennsylvania Convention Center, Philadelphia. (Image=Huons)

Huons USA (CEO Choi Jae myung), which serves as Huons Group’s US sales channel, announced on May 26 that it had participated in Convention on Pharmaceutical Ingredients Americas (CHPI Americas; formerly CHPI North America), held at Pennsylvania Convention Center, Philadelphia, U.S.

The CHPI Americas attracted thousands of attendees from more than 500 pharmaceutical companies, distributors, and R&D sectors from more than 50 countries worldwide.

Huons USA showcased the Group’s product portfolio focused on drug products and pipelines from Huons, Huonslab and Pangen Biotech.

Huons USA showcased Huons’ famous injections and eye drops. Huons’ recently FDA approved products, 1% and 2% 2mL multi dose vials for lidocaine hydrochloride injection received spotlight at the convention.

Huons USA introduced Pangen Biotech’s Erythropoietin (EPO) biosimilar and its contract development and manufacturing organization (CDMO) business provided for biopharmaceuticals. Huons USA also highlighted Huonslab’s proprietary platform technology under development. Also known as HyDIFFUZE™, it leverages recombinant human natural hyaluronidase to convert intravenous (IV) infusion to subcutaneous (SC) injection.

Huons USA was actively engaged in business discussions and meetings with buyers and distributors from countries including Latin America, Middle East, Asia, and Africa.

CEO of Huons USA Choi Jae myung said, “We focused on raising the Group’s global presence and promoting brand competitiveness at CPHI Americas. We plan to engage in further discussions with buyers and distributors at the convention for exploring new business cooperation and export opportunities.”